Phaseline

Companies › Primus Pharmaceuticals

Primus Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 4; Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Metaxalone 640 mg
Skeletal muscle relaxant
SLC6A3Phase 4Sciatica Acute; Healthy ParticipantsNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06157177Metaxalone 640 mgPhase 4Sciatica AcuteOtherNov 2026
NCT07801066Metaxalone 640 mgPhase 4Healthy ParticipantsOtherJan 2027
NCT07801066Metaxalone 640 mgPhase 4Healthy ParticipantsOtherJan 2027

Targets

SLC6A3 (1)

Companies with the same targets

Axsome Therapeutics CSPC ZhongQi Pharmaceutical Technology Currax Pharmaceuticals Otsuka AlgoTherapeutix Resilient Pharmaceuticals Gradalis Remedy Definium Therapeutics US

Companies built like this

Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm Neuraptive Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.